EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first‐line antihypertensive drugs

Cristina González-Correa, Javier Moleón iD, Sofía Miñano, Iñaki Robles-Vera, Marta Toral iD, Antonio Manuel Barranco, Natividad Martín-Morales, Francisco O'Valle, Eduardo Guerra-Hernández, Manuel Sánchez, Manuel Gómez-Guzmán iD, Rosario Jiménez and 2 more

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16410 ↗

At a glance

Journal article in British Journal of Pharmacology, 2024. Written by Cristina González-Correa and 13 co-authors. Institution: Department of Pharmacology, School of Pharmacy and Center for Biomedical Research (CIBM), University of Granada, Granada, Spain. Major MEDLINE topics: Gastrointestinal Microbiome, Antihypertensive Agents, Rats, Inbred SHR, Rats, Inbred WKY. Cited 14 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY 4.0). Funded by: Agencia Estatal de Investigación (AEI), Ministerio de Ciencia e Innovación (MCIN), Junta de Andalucía.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose This study analyses whether first‐line antihypertensive drugs ameliorate the dysbiosis state in hypertension, and to test if this modification contributes to their blood pressure (BP) lowering properties in a genetic model of neurogenic hypertension. Experimental Approach Twenty‐week‐old male Wistar Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) were untreated or treated with captopril, amlodipine or hydrochlorothiazide. A faecal microbiota transplantation (FMT) experiment was also performed by gavage of faecal content from donor SHR‐treated groups to SHR recipients for 3 weeks. Key results Faeces from SHR showed gut dysbiosis, characterized by lower acetate‐ and higher lactate‐producing bacteria and lower strict anaerobic bacteria. All three drugs increased the anaerobic bacteria proportion, captopril and amlodipine restored the proportion of acetate‐producing bacterial populations to WKY levels, whereas hydrochlorothiazide decreased butyrate‐producing bacteria. Captopril and amlodipine decreased gut pathology and permeability and attenuated sympathetic drive in the gut. Both drugs decreased neuroinflammation and oxidative stress in the hypothalamic paraventricular nuclei. Hydrochlorothiazide was unable to reduce neuroinflammation, gut sympathetic tone and gut integrity. FMT from SHR‐amlodipine to SHR decreased BP, ameliorated aortic endothelium‐dependent relaxation to acetylcholine, lowered NADPH oxidase activity, aortic Th17 infiltration and reduced neuroinflammation, whereas FMT from SHR‐hydrochlorothiazide did not have these effects. Conclusions and Implications First‐line antihypertensive drugs induced different modifications of gut integrity and gut dysbiosis in SHR, which result in no contribution of microbiota in the BP lowering effects of hydrochlorothiazide, whereas the vasculo‐protective effect induced by amlodipine involves gut microbiota reshaping and gut‐immune system communication.

Subjects

MeSH terms (MEDLINE)

Gastrointestinal MicrobiomeAntihypertensive AgentsRats, Inbred SHRRats, Inbred WKYBlood PressureAmlodipineAnimalsMaleRatsCaptoprilHypertensionHydrochlorothiazideDysbiosis

Author keywords

amlodipinecaptoprilendothelial dysfunctiongut dysbiosishydrochlorothiazidehypertensionimmune system

Substances

Antihypertensive AgentsAmlodipineCaptoprilHydrochlorothiazide

Authors and institutions

  • Department of Pharmacology, School of Pharmacy and Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.
  • Instituto de Investigación Biosanitaria de Granada, ibs. GRANADA, Granada, Spain.
  • Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Ciber de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
  • Department of Pathology, School of Medicine, University of Granada, Granada, Spain.
  • Department of Nutrition and Bromatology, University of Granada, Granada, Spain.

ORCID profiles: Javier Moleón, Marta Toral, Manuel Gómez-Guzmán

Funding

  • Agencia Estatal de Investigación (AEI)
  • Ministerio de Ciencia e Innovación (MCIN)
  • Junta de Andalucía

Cite

APA

González-Correa, C., Moleón, J., Miñano, S., Robles-Vera, I., Toral, M., Barranco, A. M., Martín-Morales, N., O'Valle, F., Guerra-Hernández, E., Sánchez, M., Gómez-Guzmán, M., Jiménez, R., Romero, M., & Duarte, J. (2024). Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first‐line antihypertensive drugs. British Journal of Pharmacology. https://doi.org/10.1111/bph.16410

Vancouver

González-Correa C, Moleón J, Miñano S, Robles-Vera I, Toral M, Barranco AM, et al. Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first‐line antihypertensive drugs. British Journal of Pharmacology. 2024. doi:10.1111/bph.16410

BibTeX
@article{GonzlezCorrea2024,
  author = {González-Correa, Cristina and Moleón, Javier and Miñano, Sofía and Robles-Vera, Iñaki and Toral, Marta and Barranco, Antonio Manuel and Martín-Morales, Natividad and O'Valle, Francisco and Guerra-Hernández, Eduardo and Sánchez, Manuel and Gómez-Guzmán, Manuel and Jiménez, Rosario and Romero, Miguel and Duarte, Juan},
  title = {Differing contributions of the gut microbiota to the blood pressure lowering effects induced by first‐line antihypertensive drugs},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16410}
}
Start for free →